GlaxoSmithKline’s chronic obstructive pulmonary disorder bronchodilator Incruse Ellipta 55mcg (umeclidinium) has been recommended for National Health Service use by the All Wales Medicines Strategy Group.

The move means that appropriate COPD patients in Wales can now get access to the once-daily long-acting muscarinic antagonist (LAMA), designed to relax airway muscles and improve airflow in and out of the lungs.

When used in combination with Relvar Ellipta 92/22mcg (fluticasone furoate/vilanterol), also endorsed by the AWMSG, it is the first and only triple therapy option for the disorder in the same type of inhaler, GSK notes.

The Scottish Medicines Consortium endorsed Incruse Ellipta back in December, following its European approval last April. The National Institute for Health and Care Excellence is not considering a full appraisal of the therapy, but may well develop an evidence summary for it.